



PantoCIN newsletter

Issue 8, December 2020



We are now recruiting the last 50 participants!
Our recruitment challenge in the next few months is to consider all eligible participants for PantoCIN
PantoCIN has a target of 160 participants



Well done to **Taranaki Base Hospital** for their recruitment over November with an amazing **SIX** patients recruited in the last three months! This site work in a hub & spoke recruitment model with Palmerston North Hospital

Welcome to... Whangarei Hospital
Investigator: **Dr Abbey Wrigley** we are very happy to be offering PantoCIN to more patients in Northland



We are very grateful to everyone, across all sites, for your continued enthusiasm and engagement, especially during this difficult year — keep up the brilliant work!

Data Monitoring Committee (DMC) 2nd meeting planned...

Data cut off is 2 February 2021 ensure all data updated to this date



Thank you to all site staff for your fantastic support of our preparation for the DMC. An initial review was completed and the DMC will meet again towards the end of the first quarter in 2021.

Will a member of the team be available to respond to queries/enter data in January? Please let us know if there will be any delays to preparing for data lock

Ensuring the quality of primary endpoint data

It is vital we receive accurate questionnaire data for each participant

- If you enter questionnaires at site: please ensure you enter questionnaire data once
- Return all paper questionnaires (scan and email) once entered

In January and February, we ask that you more regularly check in on ALEA for any new queries as we check and clean the data in line with the protocol. We will also provide reports/summaries of data for participants and help with resolving any queries you may have by email/phone.

Please do not hesitate to contact us with any questions.

Why is PantoCIN important?



- Chemotherapy-Induced Nausea and Vomiting (CINV) remains a global concern and causes substantial morbidity and distress
- Current treatments to prevent delayed CINV have limited success
- PantoCIN will help provide evidence on the use of a PPI (Pantoprazole) for treatment of delayed CINV, for breast cancer patients
- If it shows improved control of nausea then it could have applicability for other emetogenic chemotherapy regimens



On behalf of the PantoCIN team, we wish you all a very Merry Christmas, a restful holiday and a Happy New Year



Contact us

General trial queries Louise.clement@auckland.ac.nz // 09 923 4626
Data management R.cartwright@auckland.ac.nz // 09 923 4200